The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Fosfomycin: Mechanism and Resistance
Open accessAbstract
Fosfomycin, a natural product antibiotic, has been in use for >20 years in Spain, Germany, France, Japan, Brazil, and South Africa for urinary tract infections (UTIs) and other indications and was registered in the United States for the oral treatment of uncomplicated UTIs because of Enterococcus faecalis and Escherichia coli in 1996. It has a broad spectrum, is bactericidal, has very low toxicity, and acts as a time-dependent inhibitor of the MurA enzyme, which catalyzes the first committed step of peptidoglycan synthesis. Whereas resistance to fosfomycin arises rapidly in vitro through loss of active transport mechanisms, resistance is rarely seen during therapy of UTIs, seemingly because of the low fitness of the resistant organisms. Recently, interest has grown in the use of fosfomycin against multidrug-resistant (MDR) pathogens in other indications, prompting the advent of development in the United States of a parenteral formulation for use, initially, in complicated UTIs. Whereas resistance has not been problematic in the uncomplicated UTI setting, it remains to be seen whether resistance remains at bay with expansion to other indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Performance standards for antimicrobial susceptibility testing
Ferraro, M. J. (2001) · Cited by 9,667
Essential Bacillus subtilis genes
Kobayashi, K., Ehrlich, S. D., Albertini, A., Amati, G., Andersen, K. K., Arnaud, M., Asai, K., Ashikaga, S., Aymerich, S., Bessieres, P., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730515100 · Cited by 1,328
THE MECHANISM OF ACTION OF FOSFOMYCIN (PHOSPHONOMYCIN)
Kahan, F. M., Kahan, J. S., Cassidy, P. J., & Kropp, H. (1974) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1974.tb43277.x · Cited by 777
Falagas, M. E., Vouloumanou, E. K., Samonis, G., & Vardakas, K. Z. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00068-15 · Cited by 612
Phosphonomycin, a New Antibiotic Produced by Strains of Streptomyces
Hendlin, D., Stapley, E. O., Jackson, M., Wallick, H., Miller, A. K., Wolf, F. J., Miller, T. W., Chaiet, L., Kahan, F. M., Foltz, E. L., et al. (1969) · Science · doi:10.1126/science.166.3901.122 · Cited by 593
Falagas, M. E., Kastoris, A. C., Kapaskelis, A. M., & Karageorgopoulos, D. E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70325-1 · Cited by 487
Skarzynski, T., Mistry, A., Wonacott, A., Hutchinson, S. E., Kelly, V. A., & Duncan, K. (1996) · Structure · doi:10.1016/s0969-2126(96)00153-0 · Cited by 262
Biological Costs and Mechanisms of Fosfomycin Resistance in Escherichia coli
Nilsson, A. I., Berg, O. G., Aspevall, O., Kahlmeter, G., & Andersson, D. I. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2850-2858.2003 · Cited by 241
Karageorgopoulos, D. E., Wang, R., Yu, X.-H., & Falagas, M. E. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr466 · Cited by 228
Kahlmeter, G. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.suppl_1.15 · Cited by 223
Cited by
Bacterial Resistance to Antimicrobial Agents
Varela, M. F., Stephen, J., Lekshmi, M., Ojha, M., Wenzel, N., Sanford, L. M., Hernandez, A. J., Parvathi, A., & Kumar, S. H. (2021) · Antibiotics · doi:10.3390/antibiotics10050593 · Cited by 292
The Gram-negative permeability barrier: tipping the balance of the in and the out
Maher, C., & Hassan, K. A. (2023) · mBio · doi:10.1128/mbio.01205-23 · Cited by 194
Deep mutational scanning of essential bacterial proteins can guide antibiotic development
Dewachter, L., Brooks, A. N., Noon, K., Cialek, C., Clark-ElSayed, A., Schalck, T., Krishnamurthy, N., Versées, W., Vranken, W., & Michiels, J. (2023) · Nature Communications · doi:10.1038/s41467-023-35940-3 · Cited by 43
Metadata
- Authors
- Silver, L. L.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-01-06
- Volume
- 7
- Issue
- 2
- Pages
- a025262
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2571466206
- Cited by
- 320
- References
- 35
- Type
- posted content
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fosfomycin: Mechanism and Resistance. https://app.cochat.ai/papers/10.1101/cshperspect.a025262
- The paper
- Silver, L. L. (2017). Fosfomycin: Mechanism and Resistance. Cold Spring Harbor Perspectives in Medicine. https://doi.org/10.1101/cshperspect.a025262
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
